| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 data readout example | Bemarituzumab First-line FGFR2b-overexpressing gastric cancer | Phase 3 | — | - | - | ||
Phase 3 data readout example | Bemarituzumab First-line FGFR2b-overexpressing gastric cancer | Phase 3 | — | - | - | ||
Phase 3 data readout example | Bemarituzumab First-line FGFR2b-overexpressing gastric cancer | Phase 3 | — | - | - |
Recent Updates
Recently added Catalysts
Zai Lab Limited$17.73
0 (0%)
B 67Pipeline Score Fair Value Biotech · Commercial
Market Cap
2.12 B
EPS
-1.62
P/E Ratio
-
Value Trade
10.00 M
SEC Financials
Q1 2026Dilution Risk
Revenue
99.61 M
R&D Expenses
65.59 M
Operating CF
-11.91 M
Total Assets
1.10 B
Total Liabilities
433.76 M
Equity
661.98 M
D/E Ratio
12,345
-9.04 %
Week
-23 %
1 Month
-6.34 %
3 Month
-5.34 %
6 Month
-88.53 %
5 Year
-23.26 %
All Time
Cash Data
Cash Position
661.32 M
Monthly Burn
3.97 M
Runway
165.4 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
261.96 K
52 Week Range
15.96 - 44.34
% held by Insiders
1.68 %
% held by Institutions
24.09 %
Enterprise Value
1.59 B
Total Shares
112.55 M
Short %
5.9 %
Float Shares
110.66 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
B67
Pipeline Score $4.6B
Pipeline ValueFair Value
Valuation Signal17
Drugs Scored2.2x
rNPV / MCap Top 93%
Small Cap (rank 64 of 905)
Percentile RankZai Lab Limited holds a solid B-grade pipeline (67/100), with $7.1B risk-adjusted pipeline value, led by ZL-1211 in Advanced Solid Tumor (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZL-1211 Small molecule | Advanced Solid Tumor | Phase 1 | NCT05065710 | 10% | $3.3B | COMPLETED | 34 | - | - | Apr 9, 2024 | - | Sep 3, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Bemarituzumab | Gastric cancer,Gastroesophageal junction cancer | Phase 3 | 2025-06-30 | |||
Bemarituzumab | Gastric cancer,Gastroesophageal junction cancer | Phase 3 | 2025-06-30 | |||
Bemarituzumab | Gastric cancer,Gastroesophageal junction cancer | Phase 3 | 2025-06-30 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ZLAB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Zai Lab Limited (ZLAB) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
ZLAB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ZLAB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ZLAB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ZLAB Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ZLAB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ZLABZai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
Zai Lab has been granted orphan drug designation by the European Medicines Agency for Zocilurtatug Pelitecan, aimed at treating pulmonary neuroendocrine carcinomas. This designation is expected to facilitate the drug's development and potential approval in the European market. The orphan status highlights the drug's significance for rare diseases.
Read more →ZLABZai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
Zai Lab has received approval from China's NMPA for TIVDAK (tisotumab vedotin) to treat adult patients with recurrent or metastatic cervical cancer. This approval follows the successful results of the Phase 3 innovaTV 301 clinical trial. TIVDAK is indicated for patients who have experienced disease progression after chemotherapy.
Read more →ZLABZai Lab Announces Changes to Senior Leadership Team - May 21, 2026
Zai Lab Limited announced changes to its senior leadership team, including the departure of President and COO Josh Smiley. The company aims to enhance operational performance and efficiency. Zai Lab is also preparing for significant clinical data readouts in 2026 and the launch of COBENFY™ in China, alongside multiple regional regulatory approvals.
Read more →ZLABZai Lab Announces Changes to Senior Leadership Team
Zai Lab has announced changes to its senior leadership team. The article does not provide specific details about the changes or their implications for the company. This announcement may indicate a strategic shift within the organization. Further information is needed to assess the impact of these leadership changes.
Read more →ZLABZai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
Zai Lab has been granted Fast Track designation by the U.S. FDA for its investigational drug, Zocilurtatug Pelitecan (Zoci). This drug is a DLL3-targeting antibody-drug conjugate aimed at treating extrapulmonary neuroendocrine carcinomas (epNECs). The designation is expected to facilitate faster development and review of the drug.
Read more →ZLABZai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates
Zai Lab Limited reported its financial results for Q1 2026, highlighting a decrease in total revenue to $99.6 million, down 6% year-over-year. Despite challenges, the company made significant advancements in its oncology pipeline, particularly with zoci, and is preparing for the launch of KarXT in China. The company also noted increased R&D expenses and a net loss of $51 million, reflecting ongoing investments in its clinical programs.
Read more →ZLABZai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
Zai Lab Limited will report its first quarter 2026 financial results on May 7, 2026. The announcement will occur before U.S. markets open, followed by a conference call and webcast at 8:00 a.m. ET. Participants must register in advance to join the call, which will also be available for replay afterward.
Read more →ZLABZai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas
Zai Lab has announced promising clinical data for zocilurtatug pelitecan (zoci), an antibody-drug conjugate targeting DLL3, showing rapid intracranial responses in patients with extensive stage small cell lung cancer (ES-SCLC) and brain metastases. The ongoing Phase 1 trial demonstrates significant tumor regression, while additional data suggests activity in other neuroendocrine carcinomas. Zai Lab plans to present these findings at the AACR Annual Meeting 2026.
Read more →ZLABZai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases
Zai Lab has presented promising preclinical data for ZL-1503, a bispecific antibody targeting IL-13 and IL-31Rα, at the IMMUNOLOGY2026 conference. The data indicate that ZL-1503 could provide rapid itch relief and reduce inflammation in atopic diseases. The antibody demonstrated significant efficacy in suppressing symptoms over 112 days and has a favorable safety profile, supporting its advancement to Phase 1/1b clinical trials.
Read more →ZLABBoehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
Boehringer Ingelheim and Zai Lab have initiated a clinical collaboration to evaluate a dual DLL3-targeting therapy for small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs). The Phase Ib/II study will assess the safety and clinical activity of combining obrixtamig, a T-cell engager, with Zai Lab's zocilurtatug pelitecan, an antibody-drug conjugate. This collaboration aims to provide more effective treatment options for patients in need.
Read more →ZLABZai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
Zai Lab has announced a global clinical trial collaboration with Amgen to evaluate zocilurtatug pelitecan, a DLL3-targeting ADC, in combination with Amgen's IMDELLTRA therapy for extensive-stage small cell lung cancer. The Phase 1b study will assess the safety and efficacy of this combination. Zai Lab retains ownership of zoci and will supply the drug for the study.
Read more →ZLABZai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)
Zai Lab will present data on three investigational oncology therapies at AACR 2026, including zocilurtatug pelitecan (Zoci), which targets DLL3 in small-cell lung cancer. The other candidates, ZL-6201 and ZL-1222, focus on sarcoma and immunotherapy, respectively. These presentations underscore Zai Lab's commitment to innovative cancer treatments.
Read more →ZLABZai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Zai Lab Limited reported its fourth quarter and full-year 2025 financial results, showcasing significant advancements in its product pipeline and commercial business. The company highlighted strong sales growth across several products, including ZEJULA and XACDURO. Zai Lab is strategically focusing on late-stage immunology and oncology programs for 2026, alongside new collaborations to enhance market access.
Read more →ZLABZai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026
Zai Lab Limited will announce its fourth quarter and full year 2025 financial results on February 26, 2026. The announcement will precede a conference call and webcast at 8:00 a.m. ET. Participants are required to register in advance to access the call. Zai Lab is committed to developing innovative biopharmaceutical products.
Read more →ZLABZai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference
Zai Lab Limited provided an update on its strategic priorities and pipeline progress at the 44th Annual J.P. Morgan Healthcare Conference. The company is advancing its lead asset, Zoci, into Phase 3 trials and has a strong portfolio of commercial products in China. Zai Lab's dual-engine model supports both immediate performance and long-term growth, with multiple key milestones expected in 2026.
Read more →ZLABZai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference
Zai Lab Limited has announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 13, 2026. Senior management will present at 3:00 p.m. PST / 6:00 p.m. EST, with a live webcast available on the company's Investor Relations page. An archived replay will be accessible for 30 days post-event.
Read more →ZLABZai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia
Zai Lab has received approval from China's NMPA for COBENFY, a novel therapy for schizophrenia. This marks a significant advancement in treatment options, as it is the first new therapy in over 70 years. COBENFY targets M1 and M4 receptors, providing a new approach to managing schizophrenia symptoms. The approval is supported by extensive clinical trial data, indicating its potential to improve patient outcomes in China.
Read more →ZLABZai Lab Announces Updates to China’s National Reimbursement Drug List
Zai Lab Limited announced the renewal of VYVGART, NUZYRA, and ZEJULA in China's National Reimbursement Drug List for 2025. This renewal enhances patient access to these innovative therapies, reflecting their clinical value. Zai Lab aims to continue improving the affordability and accessibility of its medicines in Greater China.
Read more →Competitive Position
How ZLAB ranks across every disease it competes inCompetitive Position is a premium feature
See how ZLAB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial